Zacks Investment Research on MSN
GSK's chronic hepatitis B drug meets goals in two late-stage studies
GSK plc GSK announced positive results from two phase III studies, B-Well 1 and B-Well 2, which evaluated its investigational chronic hepatitis B (CHB) therapy called bepirovirsen. Both studies met ...
Worldwide, seven drugs have been registered for the treatment of chronic hepatitis B. These include two interferons (conventional interferon and peginterferon alfa-2a) and five oral NAs (lamivudine, ...
(Yicai) Jan. 21 -- Chinese innovative pharmaceutical company Kawin Technology plummeted today after withdrawing its ...
The Hepatitis B Co-care Scheme, allowing eligible individuals to receive a hepatitis B risk assessment, screening and ...
With a $416,000 grant from the National Institutes of Health (NIH), SLU scientists will continue work to cure hepatitis B, building on significant findings published in two recent papers. John Tavis, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results